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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not “Do BRAF
inhibitors improve survival in patients with BRAF V600E mutant melanoma?”
STUDY DESIGN: Review of primary literature sources that examined survival rates in BRAF V600E
mutant melanoma patients receiving treatment with a BRAF inhibitor.
DATA SOURCES: Two randomized controlled trials and one cohort study evaluating the use of BRAF
inhibitors in patients with BRAF V600E mutant melanoma were found using OVID, Medline, and
PubMed.
OUTCOMES MEASURED: Overall survival and progression free survival were the outcomes
measured to determine survival rates in patients with BRAF V600E mutant melanoma.
RESULTS: Chapman et al demonstrates an overall survival rate of 84% for Vemurafenib (95% CI, 7889) compared to 64% for Dacarbazine (95% CI, 56-73). Progression free survival was 5.3 months for
Vemurafenib compared to 1.6 months for Dacarbazine.
Sosman et al, a cohort study, demonstrates an overall survival rate of 58% (95% CI, 49-67) after 12
months. Progression free survival was 6.8 months (95% CI, 5.6-8.1).
Hauschild et al demonstrates an overall survival rate of 57% for Dabrafenib compared to 22% for
Dacarbazine. Progression free survival was 5.1 months for Dabrafenib compared to 2.7 months for
Dacarbazine.
CONCLUSIONS: All studies reported longer periods of progression free survival and an increase in
overall response rates. This suggests that BRAF inhibitors improve survival in patients with V600E
mutant melanoma.
KEY WORDS: Melanoma; BRAF inhibitor; Survival
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INTRODUCTION

Melanoma is a form of skin cancer that affects melanocytes. Melanocytes are found in
the epidermis and produce melanin, the major pigment responsible for skin color. Melanoma is
sometimes described as the “ugly duckling sign”, meaning that it doesn’t look like other nevi.
Typically nevi suspicious of melanoma are asymmetric, have irregular borders, appear black or
brown in color, are larger than 6 mm in diameter, and evolve in size, shape, or color (ABCDE
rule). Melanoma most commonly occurs on sun exposed areas of the skin but not exclusively.
In addition, the incidence of melanoma increases with age, however younger patients may also
be diagnosed with melanoma.1
Skin cancer is the most commonly diagnosed cancer. Melanoma accounts for less than
2% of skin cancer but it is the most deadly. The American Cancer Society estimates 76,100 new
cases and 9,710 deaths from melanoma in the United States for 2014. In addition, the number of
new cases of melanoma in the US has been increasing for the past 30 years.1 Studies examining
all stages of disease, indicate the annual cost of treatment ranges from $44.9 million to $932.5
million.2 It is estimated that there are 17.4 million visits from 1979 to 2010.3
Risk factors of melanoma include UV light exposure, presence of moles, fair skin,
freckling, light hair, and positive family history. However, it is not known how these risk factors
cause melanoma. It is known that patients with melanoma are at a higher risk of recurrence.
However, methods to lower the risk of melanoma progression or recurrence remain unknown.1
Early stages of melanoma can be treated with surgery alone but more advanced stages
require additional treatment. Surgical treatments includes wide excision, lymph node dissection,
and removal of metastatic disease. Common immunotherapy includes Ipilimumab,
Pembrolizumab, Interferon-alpha, Interleukin-2, Bacille Calmette-Guerin (BCG) vaccine, and
Imiquimod cream. Targeted therapies include BRAF inhibitors (Vemurafenib and Dabrafenib)
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and MEK inhibitors (Trametinib). Typical chemotherapies include Dacarbazine, Temozolomide,
Nab-paclitaxel, Carmustine, Cisplatin, Carboplatin, and Vinblastine. Radiation is also a common
treatment modality.2 Metastatic melanoma has a poor prognosis with an average 8-18 month
survival rate in patients with stage IV melanoma. Until 2011, Dacarbazine was the only
monotherapy approved by the FDA for metastatic melanoma.1,4
The therapies listed above all play an important role in the treatment of melanoma. 50%
of melanoma patients have a mutation of the BRAF gene. BRAF is an oncogene, meaning this
mutation increases cell proliferation. Therefore, melanocytes reproduce at an uncontrolled rate,
resulting in cancer. BRAF inhibitors are effective in shrinking tumors in half of patients with
metastatic melanoma with a mutated BRAF gene.1 This paper evaluates two randomized
controlled trials (RCTs) and one cohort study comparing the efficacy of BRAF inhibitors as a
therapy for improving survival in patients with BRAF mutant melanoma.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not “Do BRAF
inhibitors improve survival in patients with BRAF V600E mutant melanoma?”
METHODS
To examine this question, this paper focuses on patients 18 years or older with stage
III/IV BRAF V600E mutant melanoma. Interventions that were considered in literature search
included BRAF inhibitors, Vemurafenib or Dabrafenib. Types of studies examined include two
randomized control trials and one cohort study. Chapman et al is a phase 3 randomized clinical
trial comparing Vemurafenib, a BRAF inhibitor, and Dacarbazine, the FDA approved treatment
for metastatic melanoma at the time of publication. Overall survival, progression free survival,
and tumor response were measured.4 Sosman et al is a multicenter phase 2 trial cohort study
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investigating the efficacy of Vemurafenib with respect to overall response rate, progression free
survival, and overall survival.5 Hauschild et al is a phase 3 randomized controlled trial that
compared efficacy of Dabrafenib, a BRAF inhibitor, and Dacarbazine by measuring progression
free survival and overall survival.6
A detailed search was completed using OVID, Medline, and PubMed with the key words
of “Melanoma”, “BRAF inhibitors”, and “Survival”. Articles were English language peer
reviewed publications from 2011 and 2012. The criteria used for selection was based on
relevance to the proposed clinical question and patient oriented outcomes (POEMS). Inclusion
criteria were at least two randomized control trials. Exclusion criteria included patients less than
18 years of age, central nervous system metastasis, and other invasive cancers within five years
of enrollment. Statistics that were reported include RBI, ABI, NNT, and 95% Confidence
interval. Table 1 provides information regarding inclusion and exclusion criteria and specific
study interventions.

Table 1: Demographics and Characteristics of Included Studies
Study
Chapman4
(2011)

Type
RCT

#
Pts
675

Age
(yr)
>18

Inclusion Criteria
-previously untreated
stage IIIC or IV
melanoma, positive
for BRAF V600E
-Life expectancy of 3
months or longer
-ECOG performance
status of 0 (fully
active) or 1
(restricted in
physically strenuous
activity but
ambulatory)
-Adequate
hematologic, hepatic,
renal function

Exclusion
Criteria
-history of cancer
within past 5 yrs
(except basal,
squamous cell of
the skin or
cervical cancer)
-Metastasis to
CNS

W/
D
3

Intervention
960 mg of
Vemurafenib
PO BID
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Sosman5
(2012)

Cohort
Study

132

>18

Hauschild
6
(2012)

RCT

250

2193

-Stage IV melanoma
with BRAF V600
mutation &
progressive disease
after at least one prior
systemic treatment
-ECOG performance
status of 0 (fully
active) or 1
(restricted in
physically strenuous
activity but
ambulatory)
-previously untreated
stage III or IV BRAF
V600E mutant
positive melanoma
-ECOG performance
status of 0 (fully
active) or 1
(restricted in
physically strenuous
activity but
ambulatory)
-Adequate
hematologic, hepatic,
renal, & cardiac
function

-Brain metastasis
uncontrolled after
at least 3 months
of local therapy
-Other invasive
cancers within 5
yrs from
enrollment
-Inadequate
hematologic,
hepatic, & renal
function

0

960 mg of
Vemurfenib
PO BID

-surgery,
radiotherapy, or
immunotherapy
within 4 wks
-History of HIV,
G6PD, or previous
cancer in last 5 yrs
- CNS metastasis
- Corrected QT
interval >480ms,
ACS, stent
placement,
arrhythmias, heart
murmur grade 2 or
higher

80

150 mg of
Dabrafenib
PO BID

OUTCOMES MEASURED
The outcomes measured were overall survival and progression free survival. Both of
which are patient oriented evidence that matters (POEMS). These outcomes were measured
consistently across the three studies. Chapman et al measured overall survival, progression free
survival, and tumor response. Overall survival is reported as a percent of patients living out of
the total number of patients that entered a treatment group. Progression free survival was the
time from randomization to documented disease progression or death. Tumor response, a
decrease in tumor size, was also reported. Two-sided unstratified log-rank test were used to
compare survival rates in the two study groups. Event time distribution was estimated using the
Kaplan-Meier method.4 In the Sosman et al study, overall response rate was defined as the
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number of patients with complete or partial response divided by the total number of treated
patients. Progression free survival, and overall survival were estimated using the Kaplan-Meier
method while medians with two-sided 95% confidence intervals were calculated using the
Brookmeyer and Crowley method.5 Hauschild et al progression free survival and overall
survival were reported with two-sided 95% confidence intervals.6
RESULTS
At 6 months, Chapman et al reported an overall survival rate of 84% (95% CI, 78-89) for
Vemurafenib and 64% (95% CI, 56-73) for Dacarbazine. Progression free survival was 5.3
months in the Vemurafenib group and 1.6 months in the Dacarbazine group. 65% of patients
could be evaluated for tumor response. In the Vemurafenib group, 48% (95% CI, 42-55) of
patients had a detectable decrease in tumor size (2 patients had a complete response and 104 had
a partial response) with a median time to response of 1.45 months. In the Dacarbazine group,
5% (95% CI, 3-9) of patients experienced a decrease in tumor size (all partial response) with a
median time to response of 2.7 months. Tumor response rates between the two groups were
considered highly significant (P<0.001 with chi-square test).4
Sosman et al reported an overall response rate of 53% (95% CI, 44-62) for patients
receiving Vemurafenib. 6% of patients experienced a complete response while 47% received a
partial response. The progression free survival was 6.8 months (95% CI, 5.6-8.1). The median
overall survival was 15.9 months (95%, 11.6-18.3). The overall survival rates at 6, 12, and 18
months are reported in Table 2.5
Table 2: Overall Survival Rate of Patients Receiving Vemurafenib
Time
Overall Survival Rate
6 months
77% (95% CI, 70-85)
12 months
58% (95% CI, 49-67)
18 months
43% (95% CI, 33-53)
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Hauschild et al reported overall survival rate of 57% for patients receiving Dabrafenib
treatment while overall survival rate for Dacarbazine was 22%. The median time on study was
4.9 months. Progression free survival for the Dabrafenib group was 5.1 months and 2.7 months
for the Dacarbazine group. Response rates were reported as 50% (95% CI, 42.4-57.1) for
Dabrafenib and 6% (95% CI, 1.8-15.5) with a 5.5 month duration of response.6
Treatment effects of the three studies are displayed in Table 3. Relative Benefit Increase
(RBI) represents the increased chance of a positive outcome if treated with a BRAF inhibitor
compared to the chance of positive outcomes if treated with the control, Dacarbazine. Absolute
Benefit Increase (ABI) represents the actual increase in positive outcomes between the treatment
of BRAF inhibitors and Dacarabazine. Number Needed to Treat (NNT) was calculated in order
to describe the number of patients that would need to be treated in order for one patient to
survive.
Table 3: Treatment Effects of BRAF Inhibitors in Patients with BRAF V600E Mutant
Melanoma
STUDY
CER (%)
EER (%)
RBI (%)
ABI (%)
NNT (n)
4
Chapman et al
0.64
0.84
0.3125
0.2
5
Sosman et al5
n/a
n/a
n/a
n/a
n/a
Hauschild et al6
0.22
0.57
1.59
0.35
3
CER= Control Event Rate; EER= Experimental Event Rate; RBI= Relative Benefit Increase;
ABI= Absolute Benefit Increase; NNT= Number Needed to Treat
Most common side effects of Vemurafenib include cutaneous events, arthralgia, fatigue,
photosensitivity skin reactions. Cutaneous squamous cell carcinoma, keratoacanthoma, or both
developed in 18% of patients in the Chapman et al study4 and 26% of patients in the Sosman et
al study.5 Most common side effects of Dacarbazine include fatigue, nausea, vomiting, and
neutropenia.4,5,6 Dabrafenib has a similar side effect profile to Vemurafenib.6
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DISCUSSION
Treatment options for metastatic melanoma are limited. Once the BRAF mutation was
known to be associated with melanoma, BRAF inhibitors appeared to be a promising target for
therapy.5 Nearly 50% of patients with melanoma are positive for the BRAF V600 mutation.
BRAF inhibitors induce a clinical response in more than half of patients that are positive for the
BRAF V600 mutation.4,5,6 Vemurafenib was approved by the FDA in 2011 for the treatment of
metastatic melanoma. Dabrafenib was later approved in 2013.1
One of the more common toxic effects related to the use of BRAF inhibitors involved the
skin. Cutaneous squamous cell carcinoma and keratoacanthoma were removed with simple
excision. Other side effects such as arthralgia, rash, fatigue, and photosensitive reactions were
primarily managed with dose reduction.4,5,6
One important consideration is how BRAF V600 mutant melanomas become resistant to
BRAF inhibitors. In all three studies, BRAF inhibitors exhibited progression free survival for at
least 5 months. During this time melanomas responded to BRAF inhibitor target therapy. As
time progressed, tumors gained resistance and progression occurred. At this time no mechanism
of resistance has been identified but is an important consideration for further treatment and
research.4,5,6
CONCLUSION
Based on the analysis of the three studies, this selective EBM review concludes that
BRAF inhibitors do indeed improve survival in patients with BRAF V600E mutant melanoma.
Studies reported improved survival rates of at least 50% and in one study up to 80%.4,5,6 The use
of BRAF inhibitors for the treatment of BRAF V600E mutant melanoma has shown to decrease
tumor size, slow the progression of the disease, and ultimately prolong life in patients with
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metastatic disease. Future research should be aimed to minimize side effects and also to
determine the mechanism of resistance in order to prolong tumor response to treatment and
further improve survival.
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